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A B S T R A C T
Purpose
To analyze fertility in male patients treated with various combinations of radiotherapy and chemother-
apy, with or without alkylating agents, or with radiotherapy alone for Hodgkin’s lymphoma.
Patients and Methods
Follicle-stimulating hormone (FSH) levels were measured in patients with early-stage upper-
diaphragmatic disease enrolled in four European Organisation for Research and Treatment of
Cancer (EORTC) trials (H6-H9). Median follow-up after therapy was 32 months. Patients with FSH
measurement at least 12 months after end of treatment (n  355) were selected to assess
post-treatment fertility. Patients with FSH measurement 0 to 9 months after therapy (n  349)
were selected to analyze fertility recovery; of these, patients with elevated FSH ( 10 U/L;
n  101) were followed until recovery. Factors predictive for therapy-related infertility were
assessed by logistic regression.
Results
The proportion of elevated FSH was 3% and 8% in patients treated with radiotherapy only or with
nonalkylating chemotherapy (doxorubicin, bleomycin, vinblastine, dacarbazine [ABVD], epirubicin,
bleomycin, vinblastine, prednisone [EBVP]); it was 60% (P  .001) after chemotherapy containing
alkylating agents (mechlorethamine, vincristine, procarbazine, prednisone [MOPP], MOPP/doxorubicin,
bleomycin, vinblastine [ABV], bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine,
procarbazine, prednisone [BEACOPP]). After a median time of 19 months, recovery of fertility occurred
in 82% of patients treated without alkylating chemotherapy. This proportion was 30%, statistically
(P  .001) lower in those treated with alkylating chemotherapy, and median time to recovery was 27
months. The post-treatment proportion of elevated FSH increased significantly (P  .001) with the
dose of alkylating chemotherapy administered, and recovery was less frequent and slower after higher
doses. Age more than 50 years and stage II disease also contributed to poor outcome.
Conclusion
Fertility can be secured after nonalkylating chemotherapy for Hodgkin’s lymphoma. In contrast,
alkylating chemotherapy has a dismal effect, even after a limited number of cycles.
J Clin Oncol 25:2825-2832. © 2007 by American Society of Clinical Oncology
INTRODUCTION
In Hodgkin’s lymphoma (HL), the combination of
high cure rates (80% to 90%) and increasing inci-
dence in patients aged 20 to 44 years have led to a
significant number of patients with a wish to start or
complete a family after cure of HL.1-3
Male fertility after therapy for HL has been
studied.4-6 However, most studies consisted of small
series. The most informative results come from
three publications in which a dose-dependent
relationship between the number of cycles of
MOPP (mechlorethamine, vincristine, procarba-
zine, prednisone) chemotherapy and toxicity was
demonstrated.7-9 However, MOPP chemothera-
py is no longer considered the best therapy for
HL and has been replaced by newer regimens.10
Because most studies focused on MOPP-like
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chemotherapy regimens, pooling of data, larger series, and
comparison with more recent and less toxic chemotherapy
schedules is necessary.
The European Organisation for Research and Treatment of Can-
cer (EORTC) had prospectively collected data on complications after
treatment for HL since the start of the H6 trial in 1982. These data
offered the opportunity for an analysis of male fertility after five com-
bined chemoradiotherapy regimens applied between 1982 and 2004.
Moreover, the size of the data set made possible analyses on the
influence of various factors such as age, disease extension, presence of
“B” symptoms, and treatment type on the preservation of gonadal
function in males.
PATIENTS AND METHODS
Patients
A total of 2,362 male patients from 11 European countries were included
in four consecutive randomized clinical trials between August 1982 and May
2004. Protocols and informed consent were submitted to and approved by
local ethical committees. The studies were carried out in accordance with the
Helsinki Declaration. Patients were aged 15 to 70 years and presented with
histologically proven, previously untreated, classical, clinical stage I or II su-
pradiaphragmatic HL with WHO performance status grade 0 to 2. Patients
with concomitant or previous malignancies were excluded, as were patients
with serious comorbidity, those with progressive disease during treatment,
those who had received total nodal irradiation or more than one chemother-
apy regimen, and patients for whom information about the treatment actually
administered was missing. After exclusions, 2,064 male patients were suitable
for analysis (Fig 1).
Study Design: Randomized H6-H9 Trials
Patients in the H6 trial (1982-1988) received either mantle-field radio-
therapy, mantle-field and para-aortic radiotherapy, 3MOPP–mantle field
radiotherapy3 MOPP, or 3 ABVD (doxorubicin, bleomycin, vinblas-
tine, dacarbazine)–mantle field radiotherapy3ABVD.11-14 Patients in the
H7 trial (1988-1993) received either subtotal nodal irradiation (STNI) or six
cycles of EBVP (epirubicin, bleomycin, vinblastine, prednisone) followed by
involved-field radiotherapy (IF-RT) or six cycles of MOPP/ABV hybrid
(mechlorethamine, vincristine, procarbazine, prednisone/doxorubicin, bleo-
mycin, vinblastine) and IF-RT.15-17 The H8 trial (1993-1998) was a coopera-
tive trial with the Groupe d’E´tude des Lymphomes de l’Adulte (GELA).
Patients received either STNI or three, four, or six cycles of MOPP/ABV hybrid
and IF-RT or four cycles of MOPP/ABV and STNI.18 In the H9 trial (1998-
2004), also in cooperation with the GELA, patients received either six cycles of
EBVP with various doses of IF-RT or four to six cycles of ABVD and IF-RT or
four cycles of BEACOPP baseline (cyclophosphamide, doxorubicin, vincris-
tine, bleomycin, etoposide, procarbazine, prednisone) and IF-RT.19-22
Before start of treatment, data collected concerned patient characteris-
tics, initial work-up for staging of the disease, and initial work-up for further
evaluation of toxicity. After treatment, late toxicity measurements were per-
formed at completion of initial treatment and at 1, 2, 3, and 5 years thereafter
for the H6 trial; at completion of initial treatment and yearly thereafter for the
H7 trial; and at completion of initial treatment, 2 and 5 years after completion
of therapy, and every 5 years thereafter for the H8 and H9 trials. Additional
toxicity evaluations could occur in particular during the first year after therapy.
Late toxicity examinations for gonadal toxicity consisted of measurement of
several hormonal parameters: follicle-stimulating hormone (FSH), luteinizing
hormone (LH), and testosterone. In a limited number of cases, a sperm-
quality examination evaluating sperm count, motility, and morphology was
also performed.
Analysis of Fertility
Male fertility depends on the process of spermatogenesis. This process is
supported and controlled by the Sertoli cells in the testis. Sertoli cells maintain
a feedback loop with the adenohypophysis, which produces FSH to control
their function. As such, FSH levels can be seen as a reflection of Sertoli cell
function and spermatogenesis with an inverse relationship between the two.
Because data from sperm analysis were often lacking, FSH was used in this
study as the sole parameter to evaluate male fertility.
FSH was considered elevated, and thus indicative of damage to fertility, at
more than 10 U/L. Because data were issued from more than 60 laboratories
from 11 countries within a time frame of more than 20 years, some safeguards
were introduced. FSH values were dichotomized (normal/elevated): changes
from one category to the other were checked blindly (without information on
therapy) to state their significance. Small elevations crossing the upper level
were ignored if the relative change was less than 20%. Dichotomized values
were also evaluated in relation to normal FSH values for the laboratory (pro-
vided for 90% of the patients) and a conclusion made using the same ap-
proach. When no information on normal values was available, the relatively
high (and safe) cutoff point of 10 U/L was used.
Patients were selected provided that an FSH evaluation was available at
least 1 year after the end of treatment. This selection enabled comparison with
the results of published studies. An FSH evaluation before treatment was not
available for all patients. To use these cases despite the lack of initial data, we
first analyzed patients with pretreatment data and found elevated FSH levels in
only 4% (11 of 294). Elevation ranged from 11.8 to 44 U/L with a median of
19.9 U/L (normal 10 U/L). These cases were excluded from further analysis.
Next, when analyzing the follow-up of these 11 patients, we observed that in all
three patients who had received nonalkylating chemotherapy, FSH levels nor-
malized after therapy, underlining the probable lack of clinical significance of
pretreatment elevated FSH. Therefore, we argued that both the very low
percentage of patients with spontaneously elevated FSH and its presumable
lack of clinical impact justified that patients without pretreatment FSH levels
were included. Consequently, all patients without FSH evaluation before treat-
ment were also included in the study. Overall, 355 patients fulfilled those
criteria (Fig 1, Selection A).
In an attempt to study the change in FSH level with time after treatment,
a second group was defined that included all patients with at least one FSH
evaluation made during the 0- to 9-month period after treatment completion.
The same assumption as above was applied to this group that consisted of 349
patients (Fig 1, Selection B). Of these, 203 had an FSH evaluation before
treatment with a median value of 3.8 U/L (range, 0 to 10.1 U/L).
Statistical Analysis
The aim of the study was to evaluate the hormonal fertility parameters of
male patients after completion of radiotherapy alone or various combinations
of chemotherapy and radiotherapy with or without alkylating agents. The
proportion of elevated FSH after treatment and the time to fertility recovery
were the main end points analyzed. Ninety-five percent CIs for the rate were
estimated assuming a binominal distribution for the number of elevated FSH.
Patients who received chemotherapy were grouped into those who had re-
ceived regimens without alkylating agents (ABVD, EBVP) and those treated
with alkylating chemotherapy (MOPP, MOPP/ABV, BEACOPP). The num-
ber of cycles of chemotherapy was used to estimate the amount of alkylating
agents administered, counting one cycle of MOPP/ABV or BEACOPP as
equivalent to 0.5 cycles of MOPP. Patient characteristics were compared using
the Fisher’s exact test or variance analysis as appropriate. Time to recovery of
fertility was calculated from time of completion of initial planned therapy to
time of first normal FSH value, time of last toxicity examination, or January 1,
2006, whichever came first. The cumulative probability of gonadal function
recovery was calculated as [1 – the probability of surviving without normaliza-
tion of FSH]. An analysis of prognostic factors with regard to fertility recovery
was performed using Fisher’s exact test (univariate analysis) and logistic re-
gression (multivariate analysis). Factors analyzed were age (50 v50), stage
(I v II), and systemic (B) symptoms (absent v present). Probability of fertility
recovery was estimated according to the Kaplan-Meier method, and the rates
between groups were compared with use of the log-rank test. Ninety-five
percent CI for the rates were estimated using the method of Rothman and
Boice.23 Two-sided tests were used in reporting the results. Statistical signifi-
cance was defined as a P value of less than .05. The SAS statistical software
(release 9.1 TS Level 1M3; SAS Institute, Cary, NC) was used to analyze data.
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Data were selected from files stored at the Medical Research Unit, Centre
Franc¸ois Baclesse, Caen, France. Data were updated on January 1, 2006.
RESULTS
Patient characteristics for all eligible patients (N 2,064) and those
included in the two selected groups (Selection A, n 355; Selection B,
n  349) are listed in Table 1. Overall, 174 patients (33%) were
selected in both groups for a total of 530 patients studied. Patients
selected were more often issued from H7 and H8 trials in which
toxicity evaluation was mandatory according to protocol. Age, clinical
stage, and B-symptoms distributions were similar in the three groups.
Treatments actually administered are indicated in Table 2. Radiother-
apy alone was administered in one sixth of the patients, combined
chemoradiotherapy without alkylating agents in one third, and a com-
bination of radiotherapy and alkylating agents in more than one half.
Effect of Therapy on Fertility (Selection A)
In this group, time between end of treatment and FSH evaluation
ranged from 12 to 135 months, with a median of 32 months. Accord-
ing to treatment groups, median time was 30 months for patients
All male patients  (H6 - H9 trials)
N = 2,362
All patients suitable for analysis
n = 2,160
All eligible male patients
n = 2,064
Patients with at least 1 FSH evaluation
n = 867
Patients with at least 1 FSH evaluation
after treatment
n = 556
Patients excluded
 Disease progression: 63
 Total nodal irradiation: 93
 Multiple chemotherapy regimen: 46
 Missing data: 96
 No FSH evaluations: 1,197
 No FSH evaluation after treatment: 311
 Known elevated FSH before treatment: 11
Selection A
Patients with at least 1 FSH
evaluation > 1 year after the
end of treatment and normal
FSH before treatment
n = 355
Patients with at least 1 FSH evaluation
after treatment and (if known)
normal FSH before treatment
n = 545
Selection B
Patients with at least 1 FSH
evaluation 0-9 months after
the end of treatment and
normal FSH before treatment
n = 349
Fig 1. Selection of patients included
in the fertility analysis. FSH, follicle-
stimulating hormone.
Male Fertility After Hodgkin’s Lymphoma
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treated with alkylating chemotherapy, 35 months for those treated
with chemotherapy without alkylators, and 31 months for patients
with radiotherapy only. FSH was elevated in 35% of patients (126 of
355). This proportion was 3% (two of 62; 95% CI, 0% to 11%) in
patients who received radiotherapy only, 8% (eight of 101; 95% CI,
3% to 15%) in patients treated with chemotherapy without alkylators,
and 60% (116 of 192; 95% CI, 53% to 67%) in patients treated with
alkylating chemotherapy (P .001). The proportion of patients with
post-treatment elevated FSH was also influenced by age (P .001),
clinical stage (P .012), and the presence of B symptoms (P .003;
Table 3).
The amount of alkylating agents administered was estimated
using the number of cycles administered and expressed in MOPP
equivalents, counting one cycle of MOPP/ABV or BEACOPP as 0.5
MOPP equivalents. Forty-three patients received 1.5 MOPP equiva-
lents, 67 patients 2.0 or 2.5 MOPP equivalents and 82 patients three
(n  64) or six (n  18) MOPP equivalents. The proportions of
patients with post-treatment elevated FSH were 33% (95% CI, 19% to
Table 1. Patient Characteristics
Characteristic
Patients With FSH Evaluations
Eligible Male Patients
 1 Year After
Treatment (Selection A)
0-9 Months After
Treatment (Selection B)
No. % No. % No. %
No. of patients 2,064 355 17 349 17
EORTC trial
H6 287 14 43 12 32 9
H7 375 18 122 34 94 27
H8 683 33 170 48 169 48
H9 719 35 20 6 54 16
Age at random assignment, years
Median 32 30 31
Range 15-70 15-69 15-69
 30 908 44 172 48 155 44
 30 1,156 56 183 52 194 56
Clinical stage
I 736 36 112 32 113 32
II 1314 64 243 68 235 68
Unspecified 14 0 1
“B” symptoms present 545 26 85 24 80 23
Abbreviations: FSH, follicle-stimulating hormone; EORTC, European Organisation for Research and Treatment of Cancer.
Table 2. Treatments Actually Received by Patients
Treatment
Selection A (n  355) Selection B (n  349)
No. % No. %
Chemotherapy with alkylating agents 192 54 185 53
Six cycles of MOPP  mantle-field RT 18 17
Three cycles of MOPP/ABV  IF-RT 43 47
Four cycles of MOPP/ABV  IF-RT/STNI 61 56
Six cycles of MOPP/ABV  IF-RT 65† 56
Four cycles of BEACOPP  IF-RT 5 9‡
Chemotherapy without alkylating agents 101 28 107 31
Four cycles of ABVD  IF-RT 7 9
Six cycles of ABVD  IF-RT/mantle-field RT 21§ 21
Six cycles of EBVP  IF-RT 73 77¶
Radiotherapy only 62 18 57 16
IF-RT# 1 2
Subtotal nodal irradiation 61 55
Abbreviations: MOPP, mechlorethamine, vincristine, procarbazine, prednisone; RT, radiotherapy; ABV, doxorubicin, bleomycin, vinblastine; IF-RT, involved-field RT;
STNI, subtotal nodal irradiation; BEACOPP, bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone; EBVP, epirubicin,
bleomycin, vinblastine, prednisone.
One patient received only five cycles.
†One patient received only five cycles, one patient received STNI instead of IF-RT.
‡One patient received only two cycles.
§One patient received only five cycles.
One patient received only four cycles.
¶One patient received only three cycles and STNI instead of IF-RT.
#Major protocol violation, received only IF-RT, no chemotherapy.
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49%), 60% (95% CI, 47% to 72%), 75% (95% CI, 63% to 85%), and
78% (95% CI, 52% to 94%), respectively (P .001).
According to the EORTC protocols, all patients older than 50
years were considered unfavorable and received alkylating chemo-
therapy and radiotherapy. Therefore, age might not be an indepen-
dent risk factor. A stepwise logistic regression analysis was made in
which age, B symptoms, clinical stage, and type of treatment were
included as explanatory variables. Two analyses were made. In the
first one, the treatment actually received was categorized as radio-
therapy only, chemoradiotherapy not including alkylating agents,
and chemoradiotherapy including alkylating agents. In the second
analysis, the amount of MOPP equivalents was introduced in the
regression model. The first model showed that age over 50 years
(odds ratio [OR] 3.66; 95% CI, 1.42 to 9.47; P .007), stage II
disease (OR  2.32; 95% CI, 1.28 to 4.19; P  .005), and the
administration of alkylating chemotherapy (OR 22.59; 95% CI,
11.12 to 45.89; P .001) were independent factors predicting for
post-treatment elevated FSH. When the number of MOPP-
equivalent cycles of alkylating chemotherapy was introduced in the
model, age over 50 years (OR  4.37; 95% CI, 1.83 to 10.46; P 
.001), 2.0 or 2.5 MOPP equivalents (OR  3.49; 95% CI, 1.93 to
6.30; P  .001) and three to six MOPP equivalents (OR  10.85;
95% CI, 3.44 to 34.19; P .001) remained statistically significant,
supporting the assumption that age did have an independent in-
fluence on FSH values and chances of recovery.
Recovery of Fertility (Selection B)
The treatment actually administered to patients with at least
one FSH evaluation 0 to 9 months after treatment is displayed in
Table 2. Time between end of treatment and FSH evaluation for the
101 patients (29%) in whom FSH recovery was studied (post-
treatment elevated FSH and further evaluations) ranged between
11 and 119 months, with a median of 26 months. According to
treatment groups, median time was 27 months for patients treated
with alkylating chemotherapy, 18 months for those treated with
chemotherapy without alkylators, and 20 months for patients with
radiotherapy only.
At first evaluation (median time, 3 months after end of treat-
ment), 55% of patients (191 of 349) had elevated FSH. Recovery
occurred in 42% (42 of 101) at a median time of 23 months (range, 10
to 67 months) after end of treatment (Fig 2). It was 24 months (range,
14 to 67 months) for patients treated with alkylating chemotherapy, 16
months (range, 10 to 39 months) for those treated with chemotherapy
without alkylators, and 18 months (range, 10 to 34 months) for pa-
tients with radiotherapy only (P .001). The cumulative probability
of gonadal function recovery by treatment type is illustrated in Figure
3A, where a statistically significant (P  .001) trend was noticed.
Besides treatment, no factors influenced recovery.
The influence of the amount of MOPP equivalents was also
studied. Among the 79 patients treated with alkylating chemotherapy,
20 received 1.5 MOPP equivalents, 24 received two MOPP equiva-
lents, 23 received three MOPP equivalents and 12 patients received six
MOPP equivalents. The cumulative probability of gonadal function
recovery by treatment intensity is illustrated in Figure 3B, in which
patients (n  22) treated without alkylators, as well as patients
(n  20) who received one or 1.5 MOPP equivalents and those
(n  59) who received two to six MOPP-equivalent cycles, were
Table 3. Relationships Between Patient and Treatment Characteristics and Late
( 1 year after the end of treatment) Change in FSH Level (Selection A, n  355)
Characteristic
FSH Level  1 Year After Treatment
P
Elevated Normal
No. % No. %
Age at random assignment, years  .001
 30 54 43 118 52
 30 and  50 49 39 101 44
 50 23 18 10 4
Clinical stage
I 29 23 83 36 .012
II 97 77 146 64
“B” symptoms
Present 42 33 43 19 .003
Absent 84 67 186 81
Treatment type  .001
Radiotherapy only 2 2 60 26
Radiotherapy and chemotherapy 124 98 169 74
Type of chemotherapy  .001
Without alkylating agents 8 6 93 55
Containing alkylating agents 116 94 76 45
Alkylating chemotherapy  .001
1.5 cycles 14 12 29 38
Two cycles 40 35 27 36
Three cycles 48 41 16 21
Six cycles 14 12 4 5
Abbreviations: FSH, follicle-stimulating hormone; MOPP, mechlorethamine, vincristine, procarbazine, prednisone.
Expressed in MOPP-equivalent cycles.
Male Fertility After Hodgkin’s Lymphoma
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grouped. The three curves differed significantly (P .001). No other
factors were associated with recovery.
DISCUSSION
In a large cohort of patients with early-stage HL participating in the
EORTC (H6-H7) and combined EORTC-GELA trials H8-H9 in
whom FSH values were prospectively collected, we confirm that alky-
lating chemotherapy has a marked effect on male fertility. Persistent
damage was found four times more often than with other treatments.
Recovery, when occurring, also took longer. Besides treatment with
alkylating agents, factors increasing susceptibility to treatment-related
fertility damage were clinical stage II and age over 50 years at start of
therapy. The number of cycles of alkylating chemotherapy had a large
impact on the outcome of FSH when elevated after treatment in
limiting the chances and speed of recovery.
Normal
45
Elevated
12
6
6
Normal
79
Elevated
28
4
12
12
Normal
185
101 known
84 assumed
Normal
34
Elevated
151
Normal
Elevated
No further
follow-up
55
72
24
Normal
Elevated
No further
follow-up
Normal
Elevated
No further
follow-up
Normal
107
62 known
45 assumed
Normal
57
40 known
17 assumed
0
FSH before treatment FSH 0-9 months
after treatment
Follow-up of
elevated subset
A
B
C
34 (18 + 16)*
151 (83 + 68)
79 (49 + 30)
28 (13 + 15)
45 (30 + 15)
12 (10 + 2)
Fig 2. Follicle-stimulating hormone (FSH)
analysis per treatment category (Selection
B). Left part shows data before start of
treatment, middle part shows the early 0
to 9 months after treatment. FSH data and
right boxes show the outcome of patients
who experienced an elevated FSH be-
tween 0 and 9 months. (A) FSH data after
alkylating chemotherapy. (B) FSH data af-
ter nonalkylating chemotherapy. (C) FSH
data after radiotherapy only. (*) Numbers
in parenthesis are known plus assumed.
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Our results are consistent with those of Viviani et al, Marmor and
Duyck, and Specht et al, who mainly studied MOPP chemothera-
py.24-26 Although the ABVD regimen—among others—was
developed because of its fertility-sparing capacity (which we con-
firm hereby), the MOPP-ABV regimen and especially the newer
BEACOPP regimen appear to represent a step back in this regard.
Our data provide additional information on recovery of fertility
and time before recovery. Using a subset of patients with FSH evalu-
ations both during the 0 to 9 month period after treatment completion
and later on, we show that immediately after alkylating chemotherapy,
FSH was elevated in a large majority of patients, irrespectively of the
number of MOPP-equivalent cycles administered. However, time to
recovery, if any, was proportional to the number of cycles of alkylating
chemotherapy. These results are consistent with data obtained by
Da Cunha et al.7
Radiotherapy also has an influence on fertility.27 Patients in-
cluded in this study have received either mantle-field irradiation,
IF-RT (always supradiaphragmatic) or subtotal nodal irradiation, the
latter extending to the level of the fourth lumbar vertebra. Scatter
irradiation from subdiaphragmatic radiotherapy can possibly cause
gonadal damage.4 However, scatter irradiation from the para-aortic
fields is estimated to be around 1%.28 In our study, STNI had a small
effect on FSH: Patients made a fast and complete recovery, and at a
median time of 31 months after treatment, only 3% maintained an
elevated FSH. These results are in agreement with those of Shapiro et
al29 and Kinsella et al.30
Our results are based on a large group of patients with clinical
stage I or II HL representative of those included in the last four trials
conducted by the EORTC Lymphoma Group and the GELA. Further-
more, they concern data on recent chemotherapy schedules. They
highlight the risk of infertility experienced by male patients treated
with BEACOPP if this chemotherapy is preferred to ABVD as
standard treatment. One can also hypothesize that with escalated
BEACOPP, damage to fertility will be even higher. However, intensive
chemotherapy regimens such as escalated BEACOPP could be the
preferable treatment in patients with an unfavorable risk profile, such
as patients with early positron emission tomography positivity or
patients with three or more adverse factors.31 For them, the balance
between avoidance of toxic therapy and the risk of relapse—inevitably
followed by much more toxic salvage therapy—clearly points to the
selection of the most effective initial therapy even if fertility cannot
be spared.
In this study, potential sources of bias can have occurred. Firstly,
fertility could have been evaluated more often in patients at risk (ie, in
those treated with alkylating chemotherapy). However, the propor-
tions of patients included in this study were distributed equally among
the various treatment groups (Table 1). Secondly, the number of
post-treatment FSH evaluations and the time interval could have been
larger in patients with earlier abnormal FSH values. Again, this is not
the case because the occurrence and the number of evaluations ap-
peared independent of pretreatment FSH values.
In conclusion, we demonstrate in the largest series studied so far
that male fertility can be secured after chemotherapy for HL if alkylat-
ing agents are excluded. Even if an elevated FSH is observed within the
first months after the end of such chemotherapy, recovery is fre-
quently seen. In contrast, full-dose alkylating chemotherapy is associ-
ated with dismal prognosis for the majority of patients. Even if only a
limited number of cycles are administered, recovery is incomplete in
many patients. Finally, age above 50 years and stage II disease contrib-
ute to a poor outcome as far as fertility and recovery are concerned.
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Fig 3. (A) Cumulative probability of gonadal function recovery by treatment type:
radiotherapy alone (n  6), radiochemotherapy, and chemotherapy without
alkylating agents (n  16), radiotherapy and alkylating chemotherapy (n  79).
The 3-year cumulative probability was 100% (95% CI, 54% to 100%), 83% (95%
CI, 58% to 97%), and 26% (95% CI, 16% to 39%), respectively (overall
P  .001). (B) Cumulative probability of gonadal function recovery by treatment
intensity: radiotherapy alone or (radio-)chemotherapy without alkylating agents
(n  22), radiotherapy and alkylating chemotherapy including 1.5 mechloreth-
amine, vincristine, procarbazine, and prednisone (MOPP)-equivalent cycles
(n  20) or two to six MOPP-equivalent cycles (n  59). The 3-year cumulative
probability was 89% (95% CI, 70% to 98%), 63% (95% CI, 38% to 87%) and
14% (95% CI, 7% to 26%), respectively (overall P  .001). FSH, follicle-
stimulating hormone.
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